Comparative Pharmacology
Head-to-head clinical analysis: DORYX MPC versus TETRAMED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORYX MPC versus TETRAMED.
DORYX MPC vs TETRAMED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome.
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
Terminal elimination half-life is 12–15 hours in adults with normal renal function; in renal impairment (CrCl <30 mL/min), half-life may extend to >30 hours, requiring dose adjustment.
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; minor metabolic clearance accounts for 10%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic